Exposures to 1,3-dimethylamylamine-containing products reported to Texas poison centers.

Abstract

1,3-Dimethylamylamine (DMAA) is an ingredient in a number of weight loss and exercise performance enhancing products. However, information on the safety of DMAA-containing products is limited. Exposures to DMAA-containing products reported to Texas poison centers during 2010-2011 were identified and selected factors were examined. A total of 56 exposures were found, of which 75.0% were reported during 2011. OxyElite Pro™ was the reported product in 80.4% of the exposures. The patients were 51.8% male and 55.4% age ≤5 years. The patient was managed on site (such as at home) in 57.1% of the cases, and the exposure was known or expected to result in an outcome that was classified as not serious in 80.4%. The most frequently reported clinical effects were tachycardia (28.6%), nausea (16.1%), and vomiting (12.5%). The most common treatments were dilution (41.1%), food (19.6%), and activated charcoal (14.3%). It should be noted that the adverse clinical effects may be due to other ingredients in the DMAA-containing products, such as caffeine.

• Authors: Mb Forrester
• Journal: Human & experimental toxicology (Hum Exp Toxicol) Vol. 32 Issue 1 Pg. 18-23 (Jan 2013) ISSN: 1477-0903 [Electronic] England
• PMID: 23060409 (Publication Type: Journal Article, Research Support, U.S. Gov't, P.H.S.)

Chemical References

• 1,3-dimethylamylamine
• Amines

Topics

• Adolescent
• Adult
• Amines (adverse effects)
• Child
• Child, Preschool
• Dietary Supplements (adverse effects)
• Female
• Humans
• Infant
• Male
• Nausea (chemically induced)
• Poison Control Centers (statistics & numerical data)
• Tachycardia (chemically induced)
• Texas
• Vomiting (chemically induced)
• Young Adult